Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Yang Li
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06088030CT.gov Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Arsenic Trioxide (this asset) | Yang Li | P2 | CCC · 53 |
| (+)-Vincristine | Tianjin Medical University Cancer Institute and Hospital | P2 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | BB |
| Nivolumab | Australian & New Zealand Children's Haematology/Oncology Group | P2 | B |
| Dexasone | Yizhuo Zhang | P3 | B |
| Isocyclophosphamide | Samsung Medical Center | P2 | B |
| Epirubicin | Children's Hospital Medical Center, Cincinnati | P2 | B |
| OTL-38 | Mayo Clinic | P3 | B |
| Irinotecan | Australian & New Zealand Children's Haematology/Oncology Group | P1/2 | B |
+42 more in the Childhood Malignant Neoplasm cohort
Other indications for Arsenic Trioxide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | BBB · 79 |
| Plasma Cell Myeloma | — | P2 | BB · 71 |
| Central Nervous System Neoplasm | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Arsenic Trioxide in Childhood Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/arsenic-trioxide-childhood-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →